Hypogonadism

Latest

Testosterone Therapy Prescribing Practices in VA Setting

Testosterone Therapy Prescribing Practices in VA Setting

Patients attending VA clinics may experience variability in testosterone prescribing practices for hypogonadism.

Long-Term Testosterone Treatment Reduced HbA1c in Men With Hypogonadism and Type 2 Diabetes

Long-Term Testosterone Treatment Reduced HbA1c in Men With Hypogonadism and Type 2 Diabetes

At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.

Adherence to Topical Testosterone Therapy in Primary and Secondary Hypogonadism

Adherence to Topical Testosterone Therapy in Primary and Secondary Hypogonadism

Low adherence to topical testosterone therapy has been linked to lowered total testosterone values and poor outcomes.

Testosterone Replacement Therapy May Protect Against Stroke, Heart Attack in Hypogonadism

Testosterone Replacement Therapy May Protect Against Stroke, Heart Attack in Hypogonadism

There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.

JAMA: Testosterone Trial Results Highlight Benefits and Risk of Testosterone Treatment

JAMA: Testosterone Trial Results Highlight Benefits and Risk of Testosterone Treatment

Studies published in JAMA and JAMA Internal Medicine highlight the benefits and risks of treating men for low testosterone.

Harmonized Testosterone Reference Ranges Established for Men

Harmonized Testosterone Reference Ranges Established for Men

Researchers have pinpointed harmonized references ranges for total testosterone levels in men.

Venous Thromboembolism Risk Higher in Men Starting Testosterone Therapy

Venous Thromboembolism Risk Higher in Men Starting Testosterone Therapy

Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.

Implantable Testosterone Pellets Associated With Small Hematocrit Increase

Implantable Testosterone Pellets Associated With Small Hematocrit Increase

Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.

Once-Daily Testosterone Solution Beneficial in Androgen Deficiency

Once-Daily Testosterone Solution Beneficial in Androgen Deficiency

Once-daily testosterone solution 2% (T-sol) is safe and improves sex drive and energy in men with androgen deficiency.

Testosterone Solution Found Safe, Effective for Hypogonadal Men

Testosterone Solution Found Safe, Effective for Hypogonadal Men

Once-daily 2% testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men.

Sign Up for Free e-Newsletters

CME Focus